In the United States there are, at present, no drugs that are specifically FDA approved to treat hearing loss. Although several clinical trials are ongoing, including one testing D-methionine that is supported by the US Army, none of these trials directly address the effect of noise exposure on cochlear spiral ganglion neurons. We recently published the first report of a systematic chemical compound screen using primary, mammalian spiral ganglion cultures in which we were able to detect a compound and others in its class that increased neurite elongation, a critical step in restoring cochlear synapses after noise induced hearing loss. Here we discuss the issues, both pro and con, that influenced the development of our approach. These considerations may be useful for future compound screens that target the same or other attributes of cochlear spiral ganglion neurons.
The bipolar spiral ganglion neurons in the cochlea transfer sound information, such as intensity, timing and frequency, from the hair cells to the cochlear nucleus in the brain stem. If that link is broken, either by hair cell dysfunction or hair cell death, by synapse degeneration or by spiral ganglion neuronal dysfunction or death, no information can pass from surviving hair cells or from any future regenerated hair cells to the brain.
Physical (acoustic over-stimulation) or chemical (antibiotics, toxins) insults can initiate a variety of pathological changes leading to injury of spiral ganglion neurons within the cochlea, some of which occur even when the hair cells are not sufficiently damaged to undergo degeneration (Furman et al., 2013; Guthrie, 2008; Kujawa et al., 2009; Lin et al., 2011; Viana et al., 2015) . Not all neurons die immediately after cochlear insult. The surviving neurons react by retracting their peripheral nerve fibers (neurites), the timing and extent of which depends upon the severity of the insult, the length of the recovery time as well as the species under study. After retraction, there is only limited spontaneous regeneration of neurites from spiral ganglion neurons. This, in turn, limits the ability of the neurites to reconnect to surviving hair cells to restore information flow. On the other hand, after cochlear insult, the centrally oriented fibers seem to degenerate along a slower time scale, and while they do survive, they maintain a generally organized frequency representation in the brain. Because the central connections are generally retained, even the damaged neurons can carry interpretable, tonotopic information from electric stimulation generated by cochlear implants.
For the military, the aim of focusing hearing loss drug discovery on spiral ganglion neurons is to design drugs that will promote one aspect of hearing regeneration after noise induced damage to cochlear neurons -that is, to reestablish a conduit to carry efficient auditory communication from the cochlea to the brain. This can take the form of developing interventions to protect or repair the neurons and to encourage the fibers to regrow toward surviving hair cells, cochlear implants, or, in the future, to regenerated hair cells. The exact biochemical pathways that prevent robust spontaneous neurite regeneration from spiral ganglion neurons are largely unknown, but can involve interference with any or all of the general mechanisms of neuronal survival, neurite initiation, neurite elongation, pathfinding and synaptogenesis. Since these mechanisms are likely to differ significantly from each other, a cocktail of different types of drugs, perhaps given along different timelines, may ultimately be necessary to successfully target the different stages of spiral ganglion neurite regeneration. Currently, there are no known drugs that are specifically approved by the FDA to promote neurite regeneration from spiral ganglion neurons. We became interested in uncovering molecular mechanisms that would promote the regrowth of retracted spiral ganglion neurites. To do this, we designed and validated a novel in vitro, small molecule screening approach to address the problem of biological regeneration of the length of spiral ganglion neurites.
Precise molecular mechanisms that control repair and regeneration in the auditory system are largely unknown. As a consequence, there is usually no specific protein to target for spiral ganglion neuron drug discovery. Thus the "target based" screening of chemical compounds, used in pharmaceutical companies to assay tens of thousands of compounds for binding, inhibition or activation of a particular molecular target (Sams-Dodd, 2005) are not yet useful at this stage of our knowledge of spiral ganglion neuron regeneration. Instead, without knowing any molecular target or mechanism or pathway, a "phenotypic screen" can be undertaken. An assay in a phenotypic screen uses as its endpoint a change in an observable physical trait, without initial regard for a molecular mechanism. Depending on the disease, phenotypic screening can be as good or better than target based screening for identifying "new molecular entities" for FDA approval (Swinney, 2013; Swinney et al., 2011) .
Drug discovery is a challenging yet critically important business. Depending on the purpose and the assay thousands of compounds might be screened to acquire "hits", then more compounds might be made and screened to optimize the candidate molecule for Phase I clinical trials (Hughes et al., 2011) . The rare compound that is promoted to a phase I clinical trial has only a 15% chance of success in acquiring full FDA approval. The biological reasons for this low success rate often have to do with the differences between in vitro and in vivo environments. Whole organism metabolism, toxicity, availability, clearance, and off target effects cannot adequately be modeled in a culture system. It is therefore especially important that the initial assay environment and measurements reflect, as closely as possible, the disease state under study, while balancing the need for speed and reproducibility.
The "rule of three" (Table 1) . Designing a phenotypic screen for auditory drug discovery takes a great deal of up-front consideration as well as painstaking validation of methodology. As it turns out, our choices for design of our neurite elongation screen, as described below, were fully consistent with the recently formulated "rule of three" (listed below) for developing predictive phenotypic assays (Vincent et al., 2015) .
1. Develop a disease relevant assay system. To mold the concept of a "disease relevant assay system" for the spiral ganglion, a clear focus on the purpose of the screen, an understanding of the available technology, and a healthy dose of pragmatism are all required. Time and resources preclude any screen on deaf animal models, which would require replicate animals for each tested compound, hearing testing, noise exposure, surgery for drug delivery, dissections, and histologic analyses for every cochlea. Drug evaluation in deaf animal models is best left to a secondary study of a limited number of promising compounds that are first highlighted in a more rapid, in vitro, screening procedure.
For in vitro studies of the auditory system, there are a variety of options that have different advantages depending on the question being addressed. Options include cell lines (Rivolta and Holley, 2002) genetically altered cells or cells from genetically altered animals (Teitz et al., 2016) , stem cells (Kwan et al., 2015; Walters et al., 2015) , explants (Mullen et al., 2012; Wang et al., 2011; Teitz et al., 2016) primary cells from the cochlea (Hegarty et al., 1997; Lie et al., 2010; Whitlon et al., 2006) or even more plentiful primary neurons from another region of the nervous system. Cell lines, genetically altered cells and stem or progenitor cells have the advantage of availability and ease of plating which allows the assaying of a large number of compounds, but they are fairly far removed from the in vivo environment. For a screen of compounds for effects on spiral ganglion neurons, it is worth considering that spiral ganglion neurons are embryonically derived from the otic vesicle (Rubel and Fritzch, 2002) , a distinction they share only with vestibular neurons. Given their bipolar morphology (a minority in the nervous system) and their unique derivation, one must consider whether these neurons have mechanisms of neurite regulation that differ from those in cell lines or even from other neurons in the nervous system. Further, because neurites in vivo do not grow in isolation and are influenced by their microenvironments, purified cells may not adequately represent the growth of spiral ganglion neurites.
An additional consideration is whether to use dissociated spiral ganglion cells or spiral ganglion explants. The advantage to explants is that the neurons remain more or less adjacent to their normal non-neural counterparts e satellite cells, fibrocytes, etc. However, each explant is not identical to the next, not only due to the dissections, but also to the place along the cochlear spiral from base to apex from which the explant is extracted. Further, in explants, counting of neurons for survival assessment is problematic and the neurites themselves often cannot be traced back to the original neuron. Neurite length has to be measured from the edge of the explant, where it is difficult to determine how far away the parent neuron lies, whether branches of the same neurite are being measured, or whether two neurites from the same neuron are being evaluated. On the other hand, dissociated cells do not have the advantage of being connected to their normally adjacent, nonneural counterparts, and the microenvironment is not as close to that in the cochlea in vivo as an explant might be. Nonetheless, even in dissociated spiral ganglion cultures, Schwann cells and neurites grow along each other in a fashion similar to that in living tissue (Whitlon et al., 2009) , suggesting that at least some of the normal signaling between the two cell types survives in dissociated mixed cultures. The advantage of dissociated cells is the larger yield, the uniform mixing of base-to-apex neurons in each culture, the ability to accurately count individual neuron cell bodies and the ability to follow a neurite from its origin to its termination. Whether to use postnatal or adult spiral ganglia depends on the question being addressed. For a study of regeneration of neurite length it might seem more "disease relevant" to use adult tissue, but there are many drawbacks to using spiral ganglia from normal or noise damaged adult cochleas. To be practical, the neurons from adult cochleas cannot presently be efficiently cultured (Vieira et al., 2007) . The survival rates are very low, the dissection is more difficult, and there is degenerating myelin contaminating the cultures. There are also the theoretical considerations. When dissociated spiral ganglion neurons are plated, their fibers are removed during the dissociation process. If one is interested in neurite elongation, the neurons must undergo two other generalized procedures first: survival and neurite initiation (the first stage of emergence from the cell soma). If the compound under study does not exert any influence on the first two processes and the neurons die or do not initiate fibers, then there is no way to assess the effects of the compounds on neurite elongation.
In general, our approach has been to opt for the best possible, most practical growing conditions for spiral ganglion neurons. For our screen, we used dissociated, primary spiral ganglia from newborn mice in the presence of serum. As it turns out, the choice was especially advantageous. The initial hit we found in the screen for promoters of neurite elongation was an HMG-CoA reductase inhibitor (a statin). Had we chosen to screen compounds on other neurons, certain cell lines, transformed cells, or stem cells, we would have missed this activity entirely because in these cells statins cause cell death (Murinson et al., 2012; Park et al., 2009; Vural et al., 2011) . Once a compound is found that stimulates elongation in spiral ganglion neurons both in the assay and subsequently in the animal, the mechanism of action, the cell types involved and the ancillary proteins or conditions promoting the effect of the compound can then be evaluated in depth. The possibility always remains that despite our best estimates, the in vitro study will not adequately mirror the in vivo situation. However, as we have not yet identified the mechanisms which do and do not function in an intact adult cochlea, any in vitro hit that does not function similarly in vivo gives the opportunity to focus in on the role of any inactive mechanisms in the failure of spiral ganglion neurite elongation in deafened animals.
2. Use a stimulus that has disease relevance. One may have to make an informed choice here when considering the cochlea. Noise induced hearing loss was the "disease" impetus for us and the disconnection and retraction of spiral ganglion fibers after loss of their hair cell receptors was the overall physiology we wanted to reverse. Given the limitations on the use of adult cochleas, we felt that the closest we could get to the physiologic damage was to dissociate the cells of the spiral ganglion, thereby removing the initially existing neurites from the spiral ganglion neurons. The newborn neurons survive well in culture. Once the neurites re-initiated and began to grow, the compounds were then added and the effects on the neurite length was determined. Dissociated culture, in which both neurites are removed from the neuron, necessarily differs from the situation in a damaged cochlea where the peripheral fiber retracts while maintaining connections of the central fibers. Whether or not this will adequately represent our "disease" state, will be determined by elevating hits to evaluation in whole animal studies.
3.
Have an assay readout in proximity to the clinical endpoint. For example, an appropriate assay readout would be number of neurons if the search is for survival promoting compounds; number of neurites if the search is for neurite initiation promoting compounds. For an elongation promoting assay, the readout is also straightforward: measurement of an increase in the farthest extent a neurite grows. In vitro, there is no way to know which neurite is the peripheral neurite. We therefore chose to evaluate the longest neurite from each neuron, measure its farthest, uninterrupted length, and rely on validation in vivo of any hits to demonstrate which or both neurites were increased in length.
Although promoting neurite elongation is important for repair and regeneration throughout the nervous systems, phenotypic screens that specifically measure increases in the farthest extent a neurite grows for the purpose of identifying neurite elongating factors have been rarely reported. Various measurements of neurite growth have been explored including 1) labeling density for neurite specific markers (which cannot distinguish between changes in marker expression, neurite branching, neurite length or increased neurite initiation); 2) the number of neurons with neurites (which may represent both neurite initiation and/or loss of a specific population of neurons or neurites); 3) branch number (which indicates the number of forks in the path of the neurite, perhaps measuring neurite mass, but not, necessarily, reflecting the farthest extent a neurite can grow), 4) total neurite branch length (which adds all segments of a primary neurite and each of its branches, not necessarily representative of the length of a primary neurite); and 5) total primary neurite length per neuron (which measures the sum of the distance of the farthest extent of all neurites from the cell body and is dependent on neurite number as well as length). However, small molecule screens that directly measure neurite elongation are few (Al-Ali et al., 2013; Yagi et al., 2015) .
To this "rule of 3", it is important to emphasize extensive assay validation and demonstration of reproducibility of the procedure and results. For our screen, we developed the dissociated spiral ganglion assay (Whitlon et al., 2006) , characterized it (Whitlon et al., 2007 (Whitlon et al., , 2009 , quantified it in terms of survival (Whitlon et al., 2006 (Whitlon et al., , 2007 , then measured by hand the neurite lengths from photographic images (Whitlon et al., 2007) . We demonstrated that the Rho kinase inhibitor H1152 increased neurite lengths in our cultures, then showed that automated imaging of immunolabeled cultures and computer assisted measurements would reproduce our manual photography measurements (Lie et al., 2010) . Finally, we reduced the size of the cultures from wells in a 96 well plate to wells in a 384 well plate. To reach the final protocol required testing of various computer programs for detection and measurement of neurons and neurites, evaluation of various pipetters, plates, reagents, and procedures for diluting and adding chemical compounds, and the incorporation of both positive (H1152) and negative (DMSO, water) controls on every plate. The key to the entire process was to ensure reproducibility from experiment to experiment, and from year to year. An example of the neurite length analysis is presented in Fig. 1 .
Careful consideration of the appropriateness of the chemical compound library to be screened is important (Dandapani et al., 2012) . We were able to screen 440 compounds from the NIH Clinical Collection with this assay. The NIH Clinical Collection is a library of compounds with a history of use in clinical trials for a variety of diseases and therefore have well-characterized safety profiles. The HMG-CoA reductase inhibitor cerivastatin was the only "hit" from the screen, but subsequent dose response studies of a variety of statins demonstrated activity, albeit at different optimal concentrations, of most, but not all of the compounds in the order
tin up to 25 mM was inactive in the assay (Whitlon et al., 2015) . In addition, we show that the statin pitavastatin but not rosuvastatin (Fig. 1 ) also has neurite elongating activity in the assay. Statins are known to exert different physiological effects that can depend not only on their actual chemical structures and interactions with specific proteins, but also on their degree of lipophilicity (Sierra et al., 2011) . Although it is not presently known why pravastatin and rosuvastatin do not function below 25 mM (the highest concentration tested) in our assay, it is worth considering that these two show the most molecular polarity of the tested statin family, and their lack of neurite elongating activity in culture may be related to their low lipophilicity.
To gain insight into the mechanism underlying the promotion of spiral ganglion neurite elongation by statins, cultures were maintained with fluvastatin or cerivastatin in the presence of geranylgeraniol, a lipid known to feed into a branch of the mevalonate pathway separate from cholesterol synthesis. The neurite elongating activity of each of the two statins was blocked by this addition, indicating that the geranylgeranyl-pyrophosphate branch and not the cholesterol branch of the mevalonate pathway is responsible for the statin induced increases in neurite length. Statin depletion of geranylgeranyl-pyrophosphate and subsequent interference with the posttranslational addition of geranylgeranyl groups to proteins (for example, certain members of the Ras superfamily of small GTP binding proteins) can regulate the delivery of those proteins to their proper cellular locations and alter their enzyme or signaling activity.
As close as an in vitro screen can come to mimicking the environment in the cochlea, it will not be enough to duplicate the actual conditions in deaf animals and in humans. The final proof of efficacy and relevance must be in vivo. The point of making the assay as close as practically possible to the in vivo conditions is to increase the chance that the compounds discovered to have activity in the screen will exert the same effects in an animal. For the reasons stated above, this is not usually the case. A screen for neurite elongation is a way to narrow down a library of compounds to a workable handful that increases neurite length in vitro, but it does not, necessarily, shed light on the final length or rate of growth of a spiral ganglion neurite in vivo, or on the effects the compound may have on non-neuronal cells in the intact cochlea.
Off target effects of a drug are often negative, leading to failure before and during clinical trials. There can, however, be surprises e hence the success in "repurposing" known drugs for new diseases (Murteira et al., 2014) . In our assay, the statin drugs stimulate spiral ganglion neurite elongation by a cholesterol independent mechanism (Whitlon et al., 2015) . In addition, our positive control H1152 increases neurite length in the assay (Lie et al., 2010) . Because the statin drugs are already vetted in human medicine and H1152 is not, we focused attention on fluvastatin effects in vivo. We elevated fluvastatin to evaluation in a guinea pig model of noise induced hearing loss (Richter, Young, Richter, Smith-Bronstein, Stock, Xiao, Hoyuelos & Whitlon, unpublished) . In the very first group of experiments aimed at determining whether the drug protected the nerve fibers from degeneration at the time of noise exposure, fluvastatin demonstrated an additional unexpected effect. Delivery of the drug by mini-osmotic pump to the cochlea at the time of noise and for another 28 days, protected hearing by protecting hair cells (and therefore connected nerve fibers) from damage by noise. Although advantageous, this "side effect" of the drug in vivo illustrates the awareness one must have when elevating a hit detected in an in vitro screen to testing in an animal model.
With small changes, the screening approach we have taken for neurite elongation can be used to evaluate other aspects of neurons, and perhaps even to scale up the screen. Appropriate software, for example, can detect neurite branching, number of neurites, and neuron number. The actual data sets acquired can get quite large. The simultaneous evaluation of all of the data may be out of the reach of a small research laboratory. However, because the images are permanent, they can be assessed repeatedly to ask different questions about spiral ganglion neurons e survival, neurite number, neurite initiation, branching, and more.
Phenotypic screening on mammalian spiral ganglion neurons in a moderate throughput environment is within the reach of small research laboratories with a specific question, appropriate design and validation, and automated imaging and computer assistance. For the cochlea, the relative rarity of spiral ganglion neurons does Fig. 1 . (Left) Neurite length histograms from quadruplicate wells testing 24 separate small molecules, 2 negative (DMSO, water) and one positive (H1152) control (total 108 wells). The analysis is described in detail in Whitlon et al., 2015 . The x axis ranges from the length of the neurites from the positive control at the 25th percentile to the length of the neurites at the 75th percentile. Populations of shorter neurites plot above and to the left; longer, below and to the right. Arrowheads depict the approximate intercepts of the histograms from the negative controls (black, DMSO; white, water). Three statins are included in this assay, all at 2.1 mM. Pitavastatin calcium has two molecules of statin associated by calcium, so can be considered to be 4.2 N. H1152 concentration is 16.5 mM. At these concentrations, neurite lengths from cultures treated with rosuvastatin (red solid line) or other small molecules (black) plot near the negative controls, indicating no activity in this assay. On the other hand, both fluvastatin and pitavastatin histograms plot atop the positive control and can be considered to have neurite elongating activity in this assay. (Right) Controls alone.
not have to interfere with screening compounds on primary cultures. At the least, a hit detected in an in vitro screen carried out on spiral ganglion neurons can help to shed light on cellular mechanisms promoting or preventing changes in an observed trait. The ultimate goal is to use the knowledge gained by phenotypic screening to highlight key molecular pathways to target for development of new hearing loss drugs.
